Improved arterial compliance by a novel advanced glycation end-product crosslink breaker

D. A. Kass, E. P. Shapiro, M. Kawaguchi, A. R. Capriotti, A. Scuteri, R. C. DeGroof, E. G. Lakatta

Research output: Contribution to journalArticlepeer-review


Background - Arterial stiffening with increased pulse pressure is a leading risk factor for cardiovascular disease in the elderly. We tested whether ALT-711, a novel nonenzymatic breaker of advanced glycation end-product crosslinks, selectively improves arterial compliance and lowers pulse pressure in older individuals with vascular stiffening. Methods and Results - Nine US centers recruited and randomly assigned subjects with resting arterial pulse pressures >60 mm Hg and systolic pressures >140 mm Hg to once-daily ALT-711 (210 mg; n=62) or placebo (n=31) for 56 days. Preexisting antihypertensive treatment (90% of subjects) was continued during the study. Morning upright blood pressure, stroke volume, cardiac output, systemic vascular resistance, total arterial compliance, carotid-femoral pulse wave velocity, and drug tolerability were assessed. ALT-711 netted a greater decline in pulse pressures than placebo (-5.3 versus -0.6 mm Hg at day 56; P=0.034 for treatment effect by repeated-measures ANOVA). Systolic pressure declined in both groups, but diastolic pressure fell less with ALT-711 (P=0.056). Mean pressure declined similarly in both groups (-4 mm Hg; P

Original languageEnglish
Pages (from-to)1464-1470
Number of pages7
Issue number13
Publication statusPublished - Sep 25 2001


  • Aging
  • ALT-711
  • Arteries
  • Compliance
  • Glycosylation end products, advanced
  • Hypertension

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Improved arterial compliance by a novel advanced glycation end-product crosslink breaker'. Together they form a unique fingerprint.

Cite this